Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Marketing Surveillance Program of Idarucizumab Use in India

Trial Profile

Post Marketing Surveillance Program of Idarucizumab Use in India

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs Idarucizumab (Primary)
  • Indications Blood coagulation disorders
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 20 Dec 2018 Planned initiation date changed from 10 Dec 2018 to 26 Dec 2018.
    • 16 Nov 2018 Planned initiation date changed from 10 Nov 2018 to 10 Dec 2018.
    • 30 Oct 2018 Planned initiation date changed from 10 Oct 2018 to 10 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top